Figure 6.
Evaluation of anti-tumor effects of free peptide and micelles in a CT26 tumor model. A) Mice were inoculated subcutaneously with CT26 tumor cells (1M). Eight days later, mice were injected IV with (i) PBS, (ii) D-melittin 2 mg/kg, or (iii) DMM 5 mg peptide/kg every 4th day for a total of 3 injections. B) Tumor volume was measured every 2nd day. Significance is denoted in comparison to PBS-treated mice, calculated with a two-way ANOVA. D-melittin-treated mice had significantly smaller (***p = 0.0009) tumors than PBS mice, and DMM-treated mice had significantly smaller tumors than PBS-treated (****p < 0.0001) and D-melittin-treated (****p < 0.0001) mice. C) Survival of mice after treatment. Mice were sacrificed when euthanasia criteria were met (e.g., tumor volume > 10% of body weight). Significance is denoted in comparison to PBS-treated mice and was calculated with a Gehan-Breslow-Wilcoxon test. There was no significance (ns) in survival between PBS- and D-melittin treated groups, whereas DMM mice survived significantly longer PBS- (**p = 0.0029) and D-melittin (*p = 0.045) treated mice. (n = 6 mice/group)